Agenus Inc. (AGEN) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial TranscriptSeeking Alpha • 11/06/26
Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownZacks Investment Research • 11/06/26
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026Business Wire • 11/06/26
Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment MilestonesMarketBeat • 11/05/26
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN StudyBusiness Wire • 11/05/26
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon CancerBusiness Wire • 11/02/26
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026Business Wire • 10/25/26
Agenus to Participate in Chardan's 10th Annual Healthcare Investor ConferenceBusiness Wire • 10/09/26
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal CancerBusiness Wire • 10/08/26
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026Business Wire • 10/03/26
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026Business Wire • 10/02/26
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026Business Wire • 09/10/26
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming MechanismBusiness Wire • 08/28/26
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon CancerBusiness Wire • 08/26/26
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon CancerBusiness Wire • 08/06/26
Agenus to Provide Second Quarter 2026 Financial Report and Development UpdateBusiness Wire • 07/28/26